膜性腎症の世界市場-2023年～2030年

概要

膜性腎症の市場動向は、技術進歩や調査研究の増加に起因する研究の高まりを示します。膜性腎症の治療薬として複数のアルキル化剤が発売されています。また、免疫抑制剤も膜性腎症の予防に利用されています。

さらに、承認されたアルキル化剤の入手可能性の上昇、市場における膜性腎症患者数の増加、研究開発の増加により、膜性腎症の治療が増加しており、膜性腎症市場規模を押し上げています。

同市場は、この分野における進歩の高まりの結果、北米地域の医薬品需要が伸びています。Novartis AG、SynAct Pharma、Roxane Laboratories, Inc.、Genentech Inc.などの重要な競合企業が市場で積極的に活動しているため、市場は今後成長すると思われます。

ダイナミクス

臨床試験の増加と規制当局の承認が膜性腎症市場の成長を促進

膜性腎症市場の成長を促進する要因はいくつかありますが、その1つは、現在膜性腎症の治療法を開発している主要企業による研究開発の活発化です。各社は治療目的で様々な新製品を開発しています。いくつかの承認は市場の成長を高めています。

例えば、SynAct Pharma ABの声明によると、2022年8月16日、AP1189の化学構造の名称であるResomelagonが国際非専有名称（INN）提案リスト127に追加されました。AP1189の構造は、（2E）-2-（2E）-3- [1- (2-nitrophenyl) -1H-pyrrol-2-yl] prop-2-en-1-ylidenehydrazine-1-carboximidamideという特定の系統名を持っています。この名前がWHOのINN候補リストに含まれれば、レソメラゴンとして知られることになります。

レゾメラゴンは、メラノコルチン受容体アゴニストとして機能することで炎症の解消を促進するという事実を表すとともに、ユニークな化学構造を持つAP1189のINN命名に関するWHOガイドラインに準拠していることから、AP1189の名称として提案されています。

新興国市場における研究開発の活発化が市場成長の機会を生み出す

膜性腎症（MN）の多くはポドサイトの破壊によって引き起こされ、糸球体内で補体がその場で活性化されることによって媒介されますが、正確な分子プロセスはまだ不明です。パイロプトーシスは、組織損傷を引き起こし、炎症反応を誘発し、細胞を死滅させるプログラムされた細胞死の特異的な形態です。しかし、パイロプトーシスがMNの発症や経過に関与しているかどうかは不明です。MNでは、パイロプトーシスはポドサイトの損傷を促進する重要な因子です。

補体刺激がポドサイトにパイロプトーシスを引き起こし、試験管内でパイロプトーシスを抑制すると補体誘導性ポドサイト分解が改善されることを確認するために、研究者らはまず、MN患者の腎臓でパイロプトーシスが発症していることに気づきました。ポドサイトのミトコンドリア脱分極と活性酸素種（ROS）の形成も補体刺激によって生じましたが、ROSを抑制することでパイロプトーシスが回復しました。興味深いのは、パイロプトーシスを抑制することで、これらの作用の一部が減弱したことです。

さらに、受動的ヘイマン腎炎（PHN）を発症したラットの腎臓にはパイロプトーシスが存在し、PHNによる腎臓障害はパイロプトーシスを阻害する分子によってin vivoで緩和されることも発見しました。これらの結果は、ミトコンドリアの機能不全が、MNにおける補体誘導性のポドサイト破壊を支える重要なメカニズムであり、パイロプトーシスがこのプロセスに重要な役割を果たしていることを示しています。この結果は、パイロプトーシスが将来、MN治療のための全く新しい治療標的として使用される可能性に新たな光を当てるものです。

薬剤に伴う副作用が市場の成長を妨げる

免疫抑制剤の最も重要な副作用は感染の可能性の増大です。その他の、それほど重くない副作用としては、嘔吐、吐き気、過度の発毛、手の震えなどがあります。通常、これらの副作用は、体が免疫抑制剤に慣れてくると治まります。

次のような副作用には早急な対応が必要です：特に脱力感や倦怠感が強い、体温が100度を超える、震えがある、頻繁に尿が出る、尿を出そうとすると火照る、風邪が続く、咳が出る、などです。これらの副作用は市場の成長を抑制する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 臨床試験の増加と規制当局の承認
    • 膜性腎症の有病率の上昇
  • 抑制要因
    • 薬剤に伴う副作用
  • 機会
    • 主要企業による研究開発の高まり
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• 原発性膜性腎症
• 二次性膜性腎症

第8章 薬剤別

• アルキル化剤
  • クロラムブシル
  • シクロホスファミド
  • シスプラチン
  • エチレンイミン
  • トリアジン
• 免疫抑制剤
  • メチルプレドニゾロン
  • シクロホスファミド
  • ミコフェノール酸モフェチル
• カルシニューリン阻害薬
  • タクロリムス
  • シクロスポリン
• 副腎皮質刺激ホルモン（ACTH）アナログ製剤
• リツキシマブ

第9章 投与経路別

• 経口
• 静脈内投与
• その他

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• F. Hoffman La Roche
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• SynAct Pharma
• Roxane Laboratories, Inc
• Dr. Reddy's Laboratories Ltd.
• Genentech, Inc.
• Novartis AG
• Anant Pharmaceuticals Pvt. Ltd
• Merck KGaA
• Panacea Biotec

第14章 付録

Overview

The membranous nephropathy market trends show rising research owing to the rising technological advancements and research studies. Several alkylating agents are being launched for the treatment of membranous nephropathy. Immunosuppressants are also utilized for prevention of membranous nephropathy.

Furthermore, rising treatment for membranous nephropathy due to the rising availability of approved alkylating agents and increase in the number of membranous nephropathy cases in the market, and an increase in the research and development is driving up the membranous nephropathy market size.

The market is experiencing a growth in demand for drugs from North American areas as a result of the rising advancements in this field. With significant competitors like Novartis AG, SynAct Pharma, Roxane Laboratories, Inc, and Genentech Inc. actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Clinical Trials and Regulatory Approvals Drive the Growth of the Membranous Nephropathy Market

There are several factors driving the growth of the market one of which is rising research and development by the major key companies currently developing therapies for the treatment of membranous nephropathy. Various novel products are being developed by the companies for treatment purpose. Several approvals are taking place which are enhancing the growth of the market.

For instance, on August 16, 2022, Resomelagon, a name for the AP1189 chemical structure, has been added to the list of suggested International Nonproprietary Names (INN) Proposed List 127, according to a statement from SynAct Pharma AB. The structure of AP1189 has the particular systematic name (2E)-2-(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidenehydrazine-1-carboximidamide. If the name is included to the WHO's list of suggested INNs, it will be known as resomelagon.

Resomelagon has been suggested as a name for AP1189 in order to represent the fact that it promotes the resolution of inflammation via functioning as a melanocortin receptor agonist as well as the fact it adheres to WHO guidelines for naming INNs for the unique chemical structures.

Rising Research and Development by Key Players Creates Opportunities for the Growth of the Market

Membranous nephropathy (MN) is mostly caused by podocyte destruction, which is mediated by in situ activation of complement in the glomeruli, but the exact molecular process is still unclear. Pyroptosis is a specific form of programmed cell death that can cause tissue damage, trigger inflammatory reactions, and kill off cells. It is unclear, though, whether pyroptosis plays a role in the onset and course of MN. In MN, pyroptosis is a significant factor in the promotion of podocyte damage.

To confirm that complement stimulation caused pyroptosis in podocytes and that suppressing pyroptosis corrected complement-induced podocyte degradation in vitro, researchers first noticed the development of pyroptosis in the MN patient's kidneys. Podocytes' mitochondrial depolarization and formation of reactive oxygen species (ROS) were also generated by complement stimulation, and their pyroptosis was restored by inhibiting ROS. It's interesting to note that suppressing pyroptosis attenuated some of these effects.

In addition, they discovered that pyroptosis was present in the kidneys of rats with passive Heymann nephritis (PHN), and that PHN-induced kidney damage was alleviated in vivo by molecules that inhibit pyroptosis. These results show that mitochondrial dysfunction is a key mechanism underpinning complement-induced podocyte destruction in MN and that pyroptosis plays a significant role in this process. It sheds new light on the possibility that pyroptosis could be used as a brand-new target for therapy for MN therapy in the future.

Side Effects Associated with the Drugs will Hamper the Growth of the Market

A greater likelihood of infection is the most important adverse effect of immunosuppressive medications. Other, less severe adverse effects may include vomiting, nausea, excessive hair growth, and trembling in the hands. Usually, these adverse effects go away when the body becomes used to the immunosuppressant medications.

The following side symptoms require quick attention: feeling especially weak or weary, temperature over 100 degrees or shivers, frequently peeing or burning while trying to pass pee, persistent cold, or cough. These side effects may restrain the growth of market.

Segment Analysis

The global membranous nephropathy market is segmented based on type, drugs, route of administration and distribution channel.

Owing to High Utilization, the Immunosuppressive Agents from Treatment Segment Accounted for Approximately 40.4% of the Membranous Nephropathy Market Share

The immunosuppressive agents category from drugs held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in incidence of membranous nephropathy worldwide. Adults with primary membranous nephropathy frequently develop nephrotic syndrome. Without therapy, one-third of patients would have persistent proteinuria and about 30% of patients will undergo spontaneous remission. Within ten years, one-third of patients advance to end-stage kidney disease (ESKD).

Due to the increased risk of developing ESKD, immunosuppressive therapy is advised for patients with serious nephrotic syndrome at present and for those whose proteinuria does not improve with supportive therapy. Different immunosuppressive regimens' efficacy and toxicity are unknown. Inducing remission and lowering the number of patients who proceed towards ESKD, immunosuppressive medication likely outperforms non-immunosuppressive therapy. These advantages must be weighed against the negative effects of immunosuppressive medications, though.

Geographical Penetration

North America Accounted for Approximately 33.6% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for membranous nephropathy treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for drugs for membranous nephropathy.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of infectious disease, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of membranous nephropathy market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various drugs such as alkylating agents for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the membranous nephropathy market include F. Hoffman La Roche, SynAct Pharma, Roxane Laboratories, Inc, Dr. Reddy's Laboratories Ltd., Genentech, Inc., Novartis AG, Anant Pharmaceuticals Pvt. Ltd, Merck KGaA, Panacea Biotec among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide membranous nephropathy market. The growth of the global membranous nephropathy market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

• Primary Membranous Nephropathy
• Secondary Membranous Nephropathy

By Drugs

• Alkylating Agents
  • Chlorambucil
  • Cyclophosphamide
  • Cisplatin
  • Ethyleneimines
  • Triazines

• Immunosuppressive Agents
  • Methylprednisolone
  • Cyclophosphamide
  • Mycophenolate Mofetil

• Calcineurin Inhibitors
  • Tacrolimus
  • Cyclosporine

• Adrenocorticotropic Hormone (ACTH) Analogs
• Rituximab

By Route of Administration

• Oral
• Intravenous
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On January 30, 2023, According to Kidney International Reports, Obinutuzumab may be used in refractory MN, mostly in patients with normal kidney function, according to recent research. Obinutuzumab's effectiveness in treating refractory phospholipase A2 receptor-associated MN along with severe CKD is currently being reported by a number of studies. Despite having severe kidney dysfunction and/or advanced chronicity, the patients are benefiting with obinutuzumab therapy. The legacy impact of immunosuppressive medications in reaching remission is another issue that requires careful consideration.
• On April 6, 2022, the drugmaker Dr Reddy's introduces methylprednisolone sodium succinate generic version for injection in the US. Methylprednisolone Sodium Succinate administered via Injection by Dr. Reddy is offered in single-dose vials of 40 mg and 125 mg, each carton of which contains 25 vials, and multi-dose vials of 500 mg and 1 gm, each carton of which contains one vial.

DMI Opinion:

The global membranous nephropathy market is going to see moderate growth in upcoming years owing to rising usage of immunosuppressents for membranous nephropathy. Several researches are taking place worldwide for alkylating agents development. Numerous advances are taking place leading to the growth of market such as novel alkylating agents. According to DMI the membranous nephropathy market will see a decent growth with several novel therapies in the market.

Why Purchase the Report?

• To visualize the global membranous nephropathy market segmentation based on type, drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of membranous nephropathy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global membranous nephropathy market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drugs
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Clinical Trials and Regulatory Approvals
    • 4.1.1.2. Rising Prevalence of Membranous Nephropathy
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects Associated with the Drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Research and Development by Key Players
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Primary Membranous Nephropathy*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Secondary Membranous Nephropathy

8. By Drugs

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 8.1.2. Market Attractiveness Index, By Drugs
• 8.2. Alkylating Agents *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Chlorambucil
  • 8.2.4. Cyclophosphamide
  • 8.2.5. Cisplatin
  • 8.2.6. Ethyleneimines
  • 8.2.7. Triazines
• 8.3. Immunosuppressive Agents
  • 8.3.1. Methylprednisolone
  • 8.3.2. Cyclophosphamide
  • 8.3.3. Mycophenolate Mofetil
• 8.4. Calcineurin Inhibitors
  • 8.4.1. Tacrolimus
  • 8.4.2. Cyclosporine
• 8.5. Adrenocorticotropic Hormone (ACTH) Analogs
• 8.6. Rituximab

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Intravenous
• 9.4. Other

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.5.1. Brazil
    • 12.4.5.2. Argentina
    • 12.4.5.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. F. Hoffman La Roche *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. SynAct Pharma
• 13.3. Roxane Laboratories, Inc
• 13.4. Dr. Reddy's Laboratories Ltd.
• 13.5. Genentech, Inc.
• 13.6. Novartis AG
• 13.7. Anant Pharmaceuticals Pvt. Ltd
• 13.8. Merck KGaA
• 13.9. Panacea Biotec

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us